Dianthus Therapeutics (DNTH) Expected to Release Quarterly Earnings on Thursday

by · The Cerbat Gem

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) is anticipated to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.9445) per share and revenue of $0.46 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:00 PM ET.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. The company had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. On average, analysts expect Dianthus Therapeutics to post ($3.81) EPS for the current fiscal year and ($4.77) EPS for the next fiscal year.

Dianthus Therapeutics Trading Down 0.2%

Shares of NASDAQ:DNTH opened at $82.25 on Tuesday. The stock’s fifty day simple moving average is $92.18 and its two-hundred day simple moving average is $84.79. Dianthus Therapeutics has a 1-year low of $32.28 and a 1-year high of $117.88. The stock has a market cap of $4.51 billion, a PE ratio of -19.82 and a beta of 1.35.

Insiders Place Their Bets

In related news, CEO Marino Garcia sold 166,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $108.11, for a total value of $17,946,260.00. Following the transaction, the chief executive officer owned 65,292 shares in the company, valued at approximately $7,058,718.12. This represents a 71.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Adam Veness sold 16,167 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $110.38, for a total value of $1,784,513.46. Following the transaction, the senior vice president directly owned 3,833 shares of the company’s stock, valued at approximately $423,086.54. This trade represents a 80.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 242,429 shares of company stock valued at $26,118,913 in the last quarter. 3.02% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

DNTH has been the subject of several analyst reports. Roth Capital initiated coverage on shares of Dianthus Therapeutics in a report on Tuesday, October 27th. They issued a “buy” rating and a $113.00 target price for the company. JPMorgan Chase & Co. started coverage on shares of Dianthus Therapeutics in a research report on Friday, September 11th. They set an “overweight” rating and a $135.00 price target on the stock. Truist Financial boosted their price target on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Citigroup initiated coverage on shares of Dianthus Therapeutics in a research report on Friday, September 4th. They issued a “buy” rating and a $156.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Dianthus Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $128.54.

View Our Latest Stock Analysis on DNTH

Dianthus Therapeutics Company Profile

(Get Free Report)

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company’s research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.

Dianthus’ lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.

Further Reading